Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics develops clinical-stage neuro-active peptide therapies for stress-related neuropsychiatric disorders. Company news centers on PT00114, an investigational synthetic peptide targeting the teneurin C-terminal associated peptide, or TCAP, pathway for disorders such as treatment-resistant depression, anxiety and related stress conditions.
Recurring updates include Phase 1 safety and tolerability results, clinical-program positioning, leadership and management changes, public-market status changes including the move to OTCQB, and corporate actions tied to the completed Phytanix separation. Coverage also reflects the company’s efforts to concentrate resources and capital structure around PT00114.
Protagenic Therapeutics (Nasdaq: PTIX) will host a webinar on July 13, 2021, at 10:00 AM ET, to discuss PT00114, a potential treatment for stress-related disorders such as Depression, PTSD, Anxiety, and Addiction. The webinar features Dr. Maurizio Fava, a leading psychiatrist and principal investigator for the upcoming Phase 1/2a trial. He will provide insights into the clinical development of PT00114, a peptide aimed at regulating stress response in the brain. Interested participants can contact James Carbonara at Hayden IR for registration details.
Protagenic Therapeutics, Inc. (NASDAQ: PTIX) is set to present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021, at 8:30 AM ET. The company focuses on developing drug candidates aimed at treating stress-related neurologic disorders. Interested parties can access the presentation through the provided link. For further inquiries or to schedule one-on-one meetings, contact conference representatives or management.
Protagenic is exploring first-in-class neuro-active peptides for therapeutic applications.
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) has successfully closed an underwritten public offering of 3,180,000 units at $4.15 per unit, generating gross proceeds of approximately $13.2 million. Each unit consists of one share of common stock and a warrant for one additional share at $4.98, expiring in five years. There is also a 45-day option for underwriters to purchase up to 477,000 additional units. The offering began trading on the Nasdaq on April 27, 2021, under symbols "PTIX" and "PTIXW".
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) announced the pricing of an underwritten public offering of 3,180,000 units at $4.15 each, raising approximately $13.2 million before expenses. Each unit includes one share of common stock and a warrant priced at $4.98, expiring in five years. An additional 477,000 units can be purchased by underwriters within 45 days. The offering concludes on or around April 29, 2021, and trading for shares and warrants on Nasdaq begins April 27, 2021.